Loading clinical trials...

Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination

Understanding and Addressing the Disparity in Vaccination Coverage Among U.S. Adolescents Living in Rural Versus Urban Areas

NCT05148559•Huong Nguyen, PhD

View on ClinicalTrials.gov

Summary

Vaccine uptake in the United States is lower in rural areas, especially for HPV vaccine. Reminder/recall has been identified as an effective strategy to increase vaccination rates. This study will assess the impact by rurality of vaccine reminder notices sent via the parent's preferred method of communication on HPV vaccination among 12 year-old patients in a regional healthcare system.

Eligibility

Age

12 - 12 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Marshfield Clinic Health System patient aged 12 years with at least one preventive visit or two evaluation \& management visits with a Marshfield Clinic Health System provider in the last 36 months
•Due for at least one adolescent vaccine (HPV, MenACWY, Tdap)

Exclusion Criteria

•Primary care provider is not affiliated with Marshfield Clinic Health System
•Opted out of Marshfield Clinic Health System vaccine reminder notifications
•Missing or invalid contact information
•Deceased

Locations (1)

Marshfield Clinic Health System

Marshfield, Wisconsin, United States

Key Dates

Start Date

August 12, 2021

Primary Completion Date

November 2, 2022

Completion Date

December 1, 2026

Last Updated

November 21, 2025

Enrollment

5,451

ACTUAL participants

Conditions

Papillomavirus Vaccines

Interventions

Reminder Sent Via Preferred Method of Communication

BEHAVIORAL

Reminder Sent Via Mailed Letter

BEHAVIORAL

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898

Papillomavirus VaccinesHuman Immunodeficiency Virus+5 more

View study

SUSPENDEDNA

HPV Vaccine Confident Families

NCT06002282

Human Papillomavirus Vaccines

View study

COMPLETEDNA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination

Inclusion Criteria

Exclusion Criteria

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

HPV Vaccine Confident Families

Increasing Optimal Use of HPV Vaccination in Primary Care

Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers

AFIX to Improve HPV Vaccination